Payment overview · 2025
General Payments
$220.63
11 reported records · 6 companies
Healthcare provider profile · identity verified
Peyton A. Paisley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1083893309
Verified facts
What the public records show
CMS Open Payments records show Peyton A. Paisley, MD received $220.63 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.32 | 43.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.42 | 21.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.89 | 10.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.35 | 10.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.89 | 7.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.76 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.63 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $96.32 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $96.32 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mirtazapine | Mirtazapine | 295 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 60 |
| Trazodone Hcl | Trazodone Hcl | 203 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 17 |
| Divalproex Sodium | Divalproex Sodium | 111 | 20 |
| Eliquis | Apixaban | 94 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 41 |
| Lorazepam | Lorazepam | 91 | 19 |
| Metformin Hcl | Metformin Hcl | 86 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 20 |
| Losartan Potassium | Losartan Potassium | 80 | 22 |
| Levetiracetam | Levetiracetam | 78 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 23 |
| Gabapentin | Gabapentin | 65 | 25 |
| Donepezil Hcl | Donepezil Hcl | 64 | 14 |
| Haloperidol | Haloperidol | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 20 |
| Furosemide | Furosemide | 60 | 16 |
| Buspirone Hcl | Buspirone Hcl | 59 | 17 |
| Famotidine | Famotidine | 58 | 14 |
| Olanzapine | Olanzapine | 57 | 11 |
| Carvedilol | Carvedilol | 53 | 16 |
| Cefdinir | Cefdinir | 52 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 21 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Lisinopril | Lisinopril | 49 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 22 |
| Oxcarbazepine | Oxcarbazepine | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 18 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 15 |
| Lacosamide | Lacosamide | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 24 |
| Prednisone | Prednisone | 25 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Glipizide | Glipizide | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.63 · 11 records | PFIZER INC. | AVYCAZ, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EMBLAVEO, INGREZZA, Kerendia, NUPLAZID, PAXLOVID, TEFLARO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error